JCO：免疫治疗疗效评价标准imRECIST

2018-07-10 MedSci MedSci原创

美国Dana-Farber癌症研究所Hodi等报告，免疫治疗疗效评价标准(imRECIST)除了通过靶病灶来判断疾病进展(PD)状态外，还通过对无进展生存期(PFS)的评估，以及对疾病进展模式的分析，可以更好地识别出患者在总体生存率上的获益程度。上述结果或可用于修订疗效评价的影像学标准，以便更好地反映肿瘤免疫治疗的疗效。(J Clin Oncol. 2018年1月17日在线版 doi: 10.12

美国Dana-Farber癌症研究所Hodi等报告，免疫治疗疗效评价标准(imRECIST)除了通过靶病灶来判断疾病进展(PD)状态外，还通过对无进展生存期(PFS)的评估，以及对疾病进展模式的分析，可以更好地识别出患者在总体生存率上的获益程度。上述结果或可用于修订疗效评价的影像学标准，以便更好地反映肿瘤免疫治疗的疗效。(J Clin Oncol. 2018年1月17日在线版 doi: 10.1200/JCO.2017.75.1644)

现有评价实体瘤疗效评价标准(RECIST v1.1)不能很好地对实体瘤免疫治疗疗效和总生存进行评价。研究者采用Atezolizumab治疗非小细胞肺癌、转移性尿路上皮癌、肾癌和黑色素瘤患者的临床研究数据，对原评价标准进行修订，允许疾病进展后评价为最佳总体缓解，新病灶和非靶病灶疾病进展定义的改变。

imRECIST标准分析无进展生存，若后续扫描显示疾病控制，则初始疾病进展不计为终点事件。当RECIST v1.1与imRECIST所评估出来的患者(PFS)不一样时，另外评估患者总生存(OS)。

经过这样的修订，imRECIST标准与RECIST v1.1标准相比，患者最佳缓解率提高1%~2%，疾病控制率提高8%~13%，中位PFS延长0.5~1.5个月，延长的PFS与较长或相似的OS相关。imRECIST标准评价，出现新发病灶但靶病灶无进展的患者，其总生存与RECIST v1.1标准评价靶病灶进展的患者相似或稍短。偶尔出现一过性进展(靶病灶进展之后又缩小)的患者OS比没有靶病灶消退患者要长。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (9)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2019-05-15 lidong40

#JCO#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-07-11 xuyu

#mRECIST#

57 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-12-27 freve

#MRE#

61 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-10-25 cqlidoudou

#RECIST#

58 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2019-04-24 12498561m32(暂无昵称)

#疗效评价#

75 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2019-02-23 12498ebem19暂无昵称

#CIS#

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-07-12 huagfeg

#评价#

89 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-07-12 xqptu

#评价标准#

67 0
[GetPortalCommentsPageByObjectIdResponse(id=1891527, encodeId=c912189152ef8, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Wed May 15 17:58:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943496, encodeId=ff6e19434960a, content=<a href='/topic/show?id=0fea1219903' target=_blank style='color:#2F92EE;'>#mRECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12199, encryptionId=0fea1219903, topicName=mRECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Wed Jul 11 00:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649499, encodeId=d5c816494997d, content=<a href='/topic/show?id=134912198dd' target=_blank style='color:#2F92EE;'>#MRE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12198, encryptionId=134912198dd, topicName=MRE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bccd23846580, createdName=freve, createdTime=Thu Dec 27 03:58:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079713, encodeId=f1f420e9713f1, content=<a href='/topic/show?id=4e7515239be' target=_blank style='color:#2F92EE;'>#RECIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15239, encryptionId=4e7515239be, topicName=RECIST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Thu Oct 25 08:58:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019674, encodeId=c02520196e4bd, content=<a href='/topic/show?id=50aee0412ea' target=_blank style='color:#2F92EE;'>#疗效评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70412, encryptionId=50aee0412ea, topicName=疗效评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d81c2500028, createdName=12498561m32(暂无昵称), createdTime=Wed Apr 24 00:58:00 CST 2019, time=2019-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993606, encodeId=fdaf199360626, content=<a href='/topic/show?id=17124e60f1' target=_blank style='color:#2F92EE;'>#CIS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4760, encryptionId=17124e60f1, topicName=CIS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 23 15:58:00 CST 2019, time=2019-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444401, encodeId=e7c11444401e7, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540298, encodeId=ee82154029847, content=<a href='/topic/show?id=a1a8914e051' target=_blank style='color:#2F92EE;'>#评价标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91470, encryptionId=a1a8914e051, topicName=评价标准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fa213200151, createdName=xqptu, createdTime=Thu Jul 12 13:58:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031840, encodeId=c608103184039, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jul 11 01:58:00 CST 2018, time=2018-07-11, status=1, ipAttribution=)]
2018-07-11 内科新手

谢谢梅斯提供这么好的信息，学到很多

71 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

JCO：免疫治疗疗效评价标准imRECIST

相关资讯

科室

工具

服务